Veronique Debien

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities.

Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities.

Journal: Cell reports. Medicine

Published: June 10, 2025

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial.

Journal: Journal for immunotherapy of cancer

Published: May 07, 2025

Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.

Characteristics, Treatment Patterns and Clinical Outcomes of Women with Maghreb Origin and Diagnosis of Breast Cancer: A Single-Center, Retrospective Cohort Study.

Journal: Clinical breast cancer

Published: April 28, 2025

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Real-World 5-Year Outcomes of Patients Treated With the Adjuvant Paclitaxel Trastuzumab (APT) Regimen for Stage I HER2-Positive Early Breast Cancer: A Retrospective International Study.

Journal: Clinical breast cancer

Published: February 27, 2025

Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404].

Corrigendum to "Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: Biomarkers and beyond" [Crit. Rev. Oncol./Hematol. 200C (2024) 104404].

Journal: Critical reviews in oncology/hematology

Published: November 05, 2024

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.

Navigating the complexity of PI3K/AKT pathway in HER-2 negative breast cancer: biomarkers and beyond.

Journal: Critical reviews in oncology/hematology

Published: December 21, 2023

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Author Correction: Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Journal: Nature communications

Published: December 12, 2023

The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.

The Impact of Initial Tumor Response on Survival Outcomes of Patients With HER2-Positive Advanced Breast Cancer Treated With Docetaxel, Trastuzumab, and Pertuzumab: An Exploratory Analysis of the CLEOPATRA Trial.

Journal: Clinical breast cancer

Published: October 03, 2023

DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.

DECRESCENDO: de-escalating chemotherapy in HER2-positive, estrogen receptor-negative, node-negative early breast cancer.

Journal: Future oncology (London, England)

Published: August 23, 2023

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.

The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.

Journal: Breast cancer research and treatment

Published: August 10, 2023

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.

Journal: Nature communications

Published: July 27, 2023

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.

The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.

Journal: ESMO open

Published: July 10, 2023

Showing 1-12 of 28

Last Updated: 09/26/2026